clinical trial

(redirected from Phase 3 clinical trial)
Also found in: Dictionary, Thesaurus, Medical.

clinical trial

[¦klin·i·kəl ′trīl]
(medicine)
A research study used to find better ways to treat individuals with a specific disease, patients are evaluated after being administered a new treatment or drug.
References in periodicals archive ?
Clevudine is a potent HBV antiviral currently in Phase 3 clinical trials in Korea and has been the subject of earlier stage clinical trials under an Investigational New Drug application filed with the US FDA.
multicenter Phase 3 clinical trial and approximately 830 in our international Phase 3 clinical trial.
The companies are conducting a 600 patient Phase 3 clinical trial of the Intercept Platelet System in the United States.
Modification of the secondary endpoints in the current Phase 3 clinical trial to include molecular disease status, potentially accelerating the difference in remission between BiovaxID and control in the clinical study
Phase 3 clinical trial with approximately 600 patients, as planned, and will extend enrollment in the international Phase 3 clinical trial to increase the probability that a significant result is achieved.
NASDAQ:SOMX) today announced positive results from the company's Phase 3 clinical trial evaluating SILENOR[TM] (doxepin HCl) in elderly patients with chronic primary insomnia.
Gensia is currently investigating Arasine in Phase 3 clinical trials in patients undergoing coronary artery bypass surgery.
Somaxon's lead product candidate, SILENOR([TM]) (doxepin HCl), is in Phase 3 clinical trials for the treatment of insomnia.
The decision to discontinue the Phase 3 clinical trial of Canvaxin(TM) in patients with Stage III melanoma was based upon the recommendation of the independent Data and Safety Monitoring Board (DSMB).
Nasdaq: PGNX) today announced positive top-line results from a pivotal phase 3 clinical trial of its investigational drug, methylnaltrexone (MNTX) for the treatment of opioid-induced constipation in patients with advanced medical illness (AMI).
Nasdaq:MAXM)(SSE:MAXM) today announced that based on ongoing correspondence with the United States Food and Drug Administration (FDA), as well as consultations with external advisors, an additional Phase 3 clinical trial will be necessary to further evaluate Ceplene plus Interleukin-2 (IL-2) combination therapy for the treatment of acute myeloid leukemia (AML) patients in complete remission before applying for regulatory approval in the United States.